Posted by Michael Wonder on 13 Jan 2017
VivaGel BV granted QIDP and fast track designation by US FDA
12 January 2017 - Starpharma today announced it has been granted qualified infectious disease product and fast track designation for VivaGel BV by the US FDA.
Qualified infectious disease product and fast track designations were granted independently for both the VivaGel BV treatment and prevention indications for bacterial vaginosis (BV). This positive development recognises the high unmet medical need in the management of BV and the potential of VivaGel BV to address that need for both treatment and prevention of recurrent BV, markets estimated to be worth in excess of US$1 billion globally.
